Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease
Background and Objective: Dapagliflozin, a sodium-glucose co-transporter inhibitor, was originally developed as an oral glucose-lowering drug for the treatment of type 2 diabetes mellitus. Emerging data suggest that cardiovascular and kidney benefits extend to patients without diabetes. Limited phar...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Published: |
Adis
2021
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/25966/ https://doi.org/10.1007/s40262-020-00956-1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!